GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Interest Expense (Positive)

CGON (CG Oncology) Interest Expense (Positive)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.


CG Oncology Business Description

Industry
Traded in Other Exchanges
N/A
Address
400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.